It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…
REGULATORY
Pharma Calls for Enhancing Pre-Analysis Discussions in CEA Scheme: Chuikyo
Japan’s key reimbursement policy panel on November 12 held a hearing with pharma trade organizations on the cost-effectiveness assessment (CEA) system towards its next reform in April. Industry leaders reiterated their call for securing a reasonable timeframe for manufacturers to…
To read the full story
Related Article
- Chuikyo OKs 2022 Reform Outline for Cost-Effectiveness Assessment System
December 2, 2021
- Chuikyo OKs MHLW Proposal on CEA Price Adjustments, Analysis Team Set-Up
October 18, 2021
- Chuikyo Raises No Objections to MHLW Proposal on Revision of CEA Analysis Process
September 17, 2021
- Industry Sees Overhaul of CEA Scheme “Too Early,” Chuikyo Reps Agree
August 5, 2021
- CEA Reform Debate Going into Full Throttle, Chuikyo Consensus to Be Drawn as Early as October
August 3, 2021
REGULATORY
- Komeito’s Yoko Wanibuchi Newly Named Senior Vice Health Minister
October 4, 2024
- Panel OKs Withdrawal Rule for Conditional Nod, 2-Year Extension for Pediatric Data Protection towards PMD Act Amendment
October 4, 2024
- New Health Minister Eager to Build Pharma Ecosystem in Japan
October 3, 2024
- AMED to Assign Staff by Seed to Ensure End-to-End Support from FY2025
October 3, 2024
- New Finance Minister Vows Full Discussions with MHLW on FY2025 Revision
October 3, 2024
Long-listed products (LLPs) in Japan will be subject to a new health coverage scheme starting this October. This is expected…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…